Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.

Abstract

The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases. Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy. Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence. Twenty-one patients with metastases were also monitored during chemotherapy. Elevated CA 15-3 and TPS levels were found in 28.6% and 30.0% of patients. CA 15-3 and TPS sensitivities rose to 71.9% and 66.3% in metastatic patients, respectively. The addition of TPS to CA 15-3 increased the sensitivity up to 44.4% in the overall population, and to 87.6% in patients with metastases. During post-surgical follow-up CA 15-3 was elevated in 65.7% and TPS in 61.3% of patients with recurrence. The combination of TPS and CA 15-3 increased the overall sensitivity by 12.7%. Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment. TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.

• Authors: R D'Alessandro, M Roselli, P Ferroni, S Mariotti, A Spila, S Aloe, M D Carone, M R Abbolito, S Carlini, P Perri, A Ricciotti, C Botti, F Conti, P Vici, N R Chiappetta, F Cognetti, O Buonomo, F Guadagni
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 68 Issue 1 Pg. 9-19 (Jul 2001) ISSN: 0167-6806 [Print] Netherlands
• PMID: 11678313 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers, Tumor
• Mucin-1
• Peptides
• tissue polypeptide specific antigen

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Biomarkers, Tumor (blood)
• Breast Neoplasms (blood, diagnosis, mortality, pathology, therapy)
• Carcinoma, Ductal, Breast (blood, diagnosis, mortality, secondary, therapy)
• Carcinoma, Lobular (blood, diagnosis, mortality, secondary, therapy)
• Case-Control Studies
• Disease-Free Survival
• Female
• Fibrocystic Breast Disease (blood)
• Humans
• Italy
• Longitudinal Studies
• Mastectomy
• Middle Aged
• Mucin-1 (blood)
• Neoadjuvant Therapy
• Neoplasm Metastasis
• Neoplasm Recurrence, Local (blood, diagnosis, mortality, pathology, therapy)
• Neoplasm Staging
• Peptides (blood)
• Postoperative Period
• Sensitivity and Specificity